News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Dutch biotech, Byondis, today announced positive topline results from a Phase 3 study, which it says confirms the safety and efficacy of its antibody drug conjugate (ADC) - SYD985 - as a treatment for patients with pretreated HER2-positive locally...
Biogen pledges to share future insights about Aduhelm (aducanumab-avwa) with the scientific community as it collects more data from real-world use of the treatment, after the drug was approved by the FDA yesterday.
The Alzheimer’s Association has welcomed the FDA’s approval of aducanumab for Alzheimer’s disease, calling it ‘the beginning of a completely new future for Alzheimer’s treatments’.